TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* GHDA subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II~* Fertile females must agree to use appropriate contraceptive methods and have a negative pregnancy test at inclusion~* GH replacement therapy for more than 3 months~* Body Mass Index (BMI, kg/m2) of 22.0 to 35.0 kg/m2, both inclusive~Exclusion Criteria:~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods~* Malignant disease~* Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes~* Heart insufficiency, NYHA class greater than 2~* Subjects with diabetes with an HbA1C above 8.0%~* Diabetic receiving insulin treatment~* Stable pituitary replacement therapy for less than 3 months~* Impaired liver function~* Impaired kidney function

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male/female subjects from 16 years (where legally permitted and ethically accepted) or 18 years onwards suffering from epilepsy and having completed a previous study with brivaracetam as adjunctive treatment, which allowed access to this study~* Subjects with POS/PGS: inpatients or outpatients with epilepsy who participated in previous brivaracetam studies / programs which allow access to the present study~* Subjects with ULD: inpatients or outpatients with epilepsy who were treated with brivaracetam in previous studies / programs which allow access to the present study~* Subjects for whom the Investigator believes a reasonable benefit from the long-term administration of brivaracetam may be expected~Exclusion Criteria:~* Severe medical, neurological and psychiatric disorders, or laboratory values which may have an impact on the safety of the subject~* Poor compliance with visit schedule or medication intake in previous brivaracetam study~* Participation in any clinical study of another investigational drug or device during the study~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (Type: EXPERIMENTAL): Flexible dosing, can up and down titrate as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant with Grade I or Grade II acute sprain of the lateral ankle within 24 hours before screening visit~* Participant with self-assessed pain intensity score after movement (5 steps) at the site of the ankle sprain that is \>= 5 as measured on a 0-10 NRS rating.~* Participant with a peri-malleolar edema (sub-malleolar perimeter difference of \>=20mm between injured and uninjured ankle)~Exclusion Criteria:~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.~* Participant who had medication that could interfere with the subject's perception of pain since experiencing ankle sprain.~* Pregnancy , Breast Feeding and Substance Abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin patch (Type: EXPERIMENTAL): Indomethacin patch to be applied on the sprained ankle twice a day (BID).
- Placebo patch (Type: PLACEBO_COMPARATOR): Placebo patch to be applied on the sprained ankle BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater or equal to 18 years~2. Occipital neuralgia diagnosed based on history \& physical exam and diagnostic local anesthetic blocks, or migraine with occipital nerve(s) tenderness that responds to diagnostic blocks.~   a. Greater or equal to 50% relief based on diagnostic local anesthetic block of the greater and/ or lesser occipital nerves that lasts for at least 90 minutes with lidocaine or 3 hours with bupivacaine or ropivacaine 20~3. Baseline Numerical Rating Scale average pain score \> 4/10~4. Frequency of greater or equal to 4/10 pain for at least 10 days per month~Exclusion Criteria:~1. Untreated coagulopathy~2. Automatic implantable cardiac defibrillator or pacemaker that cannot be temporarily disabled for medical reasons~3. Previous pulsed radiofrequency~4. Other sources of headache, such as tension-type headache, cervicogenic headache, migraine headache without occipital neuralgia, and other causes (e.g. tumors, congenital abnormalities etc.). Those that can be confused with ON must be excluded based on history and exam (e.g. cervicogenic headaches), symptoms (tension-type headache), response to blocks (all of the above); and lab work (temporal arteritis, which would be confirmed by biopsy after an elevated erythrocyte sedimentation rate).~5. Serious medical or uncontrolled or severe psychiatric -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Pulsed radiofrequency + local anesthetic injection (Type: EXPERIMENTAL): Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
- Corticosteroid injection + sham pulsed radiofrequency (Type: ACTIVE_COMPARATOR): Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* Histologically confirmed locally advanced or metastatic clear cell renal cell carcinoma that has progressed during or after at least two prior therapeutic regimens which must include vascular endothelial growth factor (VEGF)-targeted therapy and checkpoint inhibitor therapy or that has otherwise failed such therapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1~* Estimated life expectancy of longer than 3 months~* Adequate organ function at screening~Exclusion Criteria:~* History of untreated brain metastasis or leptomeningeal disease or spinal cord compression~* Failure to recover from reversible effects of prior anti-cancer therapy~* Has received systemic therapy or radiation therapy within 2 weeks prior to first dose~* History of solid organ or stem cell transplantation~* Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronic immunosuppressive therapy~* Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months prior to first dose~* Current use of immune checkpoint inhibitors~* Use of an investigational agent or device within 2 weeks prior to dosing, or current participation in an investigational study~* Known HIV, hepatitis B or hepatitis C~* History of other clinically meaningful disease~* Major surgery within 4 weeks of Screening~* Active malignancy requiring therapy other than ccRCC within 3 years of study entry~Note: Other eligibility criteria may apply per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARO-HIF2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2~* Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2~* All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 5 (randomization)~Exclusion Criteria:~* Severe hypertension~* Pregnant or nursing (lactating) women~* Pre-menopausal women not taking accepted form of birth control~* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1~* History of cardiovascular conditions~* Uncontrolled Type 1 or Type 2 diabetes mellitus~* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amlodipine 10 mg (Type: EXPERIMENTAL): Amlodipine 10 mg
- Aliskiren/Amlodipine 150/10 mg (Type: EXPERIMENTAL): Aliskiren/Amlodipine 150/10 mg
- Aliskiren/Amlodipine 300/10 mg (Type: EXPERIMENTAL): Aliskiren/Amlodipine 300/10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults in the following risk groups: physicians, nurses, respiratory therapists, microbiology laboratory personnel working at UCSF Benioff Children's Hospital Oakland or the University of Massachusetts Medical School as well as medical students attending accredited U.S. medical schools~* Able to comprehend and follow all required study procedures~* In good health as determined by a brief medical history~* For females of child bearing age a negative urine pregnancy test will be required~Exclusion Criteria:~* Are not in the risk groups summarized above~* Have not given or are unable to give written informed consent to participate in the study~* Females of child bearing potential who are pregnant, or planning on becoming pregnant during the study period.~* Persons with a past history of having Guillain-Barré Syndrome (GBS), or a family history of GBS in a parent or sibling.~* Persons with presence or suspected presence of serious chronic disease including but not limited to: chronic cardiac disease, autoimmune disease, diabetes, hepatitis B/C, HIV, progressive neurological disease or seizure, leukemia, lymphomas, or neoplasm.~* Have participated in any other investigational drug or received any other vaccine within the last 30 days.~* Received a dose of a meningococcal serogroups A, C, Y, W conjugate vaccine within the previous 30 days or wish to receive a dose of this vaccine during the six month study period.~* Have a history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous dose of Trumenba~* Have experienced fever (oral temperature above 38.0°C) within the past 3 days or are suffering from a present acute infectious disease~* Are planning to leave the area of the study site before the end of the study period~* Have obesity (BMI higher than 33); or 11.~* With any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Open Label: MenB-FHbp (Type: EXPERIMENTAL): Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion critieria:~* Histologically or cytologically confirmed diagnosis of stage IIIB or IV NSCLC that carries an ALK rearrangement, as per the FDA-approved FISH assay (Abbott Molecular Inc.).~* Age 18 years or older at the time of informed consent.~* Patients must have NSCLC that has progressed during therapy with crizotinib or within 30 days of the last dose~* Patients must have received 1-3 lines of cytotoxic chemotherapy (of which 1 must have been a platinum doublet) to treat their locally advanced or metastatic NSCLC~* Patients must have a tumor tissue sample available, collected either at the time of diagnosis of NSCLC or any time since.~* Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea/vomiting and/or grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.~Exclusion criteria:~* Patients with known hypersensitivity to any of the excipients of LDK378.~* Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.~* History of carcinomatous meningitis.~* Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.~* Clinically significant, uncontrolled heart disease~* Systemic anti-cancer therapy given after the last dose of crizotinib and prior to starting study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDK378 (Type: EXPERIMENTAL): Patients treated with ceritinib/LDK378 750 mg once-daily, fasted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient eligible for emergency surgery on cardiopulmonary bypass pump for a thoracic aortic dissections AND~* Age \> 18 years AND~* Consent obtainable from patient or by proxy (independent physicians and/or next of kin)~Exclusion Criteria:~* Documented refusal of blood transfusion OR~* FFP transfusion before randomization OR~* Aortic dissection due to trauma OR~* Treatment with GPIIb/IIIa inhibitors \< 24h from screening OR~* Withdrawal from active therapy OR~* Expected to die \< 24h OR~* Previously within 30 days included in a randomized trial, if known at the time of enrolment~* Known IgA deficiency with documented antibodies against IgA~* Known hypersensitivity to OctaplasLG®: the active substance, any of the excipients (Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100))~* Known severe deficiencies of protein S~* Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a negative serum-hCG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OctaplasLG® (Type: ACTIVE_COMPARATOR): replacement to bleeding
- Standard fresh frozen plasma (Type: PLACEBO_COMPARATOR): replacement to bleeding

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;~* Visual acuity of 20/40 to 20/80 or better (Snellen equivalent).~Exclusion Criteria:~* Clinically relevant ophthalmic or systemic conditions may be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): IOP Dorzolamide-Timolol-Brimonidine group
- B (Type: ACTIVE_COMPARATOR): IOP dorzolamide-timolol group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are treated with Riociguat for CTEPH~Exclusion Criteria:~* Patients who are contraindicated based on the product label

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Riociguat treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Postoperative Outcomes Between Surgeries Anaesthetized With Propofol and Inhalational Anaesthetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Postoperative outcomes from Acute Pain Service data bank between Jan 2015 and Dec 2017 in Queen Mary Hospital would be retrieved;~2. Surgeries with general anaesthesia by either propofol or inhalational anaesthetics.~Exclusion Criteria:~1. Essential data missed;~2. Surgical types with small sample size below 30 for the data collection period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Group propofol (Type: None): Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
- Group inhalation anaesthetics (Type: None): Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TX2® Low Profile TAA Endovascular Graft

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Descending thoracic aneurysm with diameter ≥ 5.0 cm~* Descending thoracic aneurysm with a history of growth ≥ 0.5 cm per year~* Descending thoracic degenerative or atherosclerotic ulcer ≥ 10 mm in depth and 20 mm in diameter~Exclusion Criteria:~* Less than 18 years of age~* Life expectancy less than 2 years~* Pregnant or breastfeeding or planning on becoming pregnant within 60 months~* Unwilling to comply with the follow-up schedule~* Inability or refusal to give informed consent~* Less than 30 days beyond primary endpoint for other investigative drug or device study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete